Repligen said to have rejected $14 billion takeover offer from Catalent, reports StreetInsider

Betaville notes rivals at StreetInsider have picked up on the Repligen Corporation takeover rumour that has been doing the rounds in the last few days.

According to StreetInsider, Catalent - a US-listed biopharmaceutical company - has been circling Repligen, which makes materials used in the manufacture of biological drugs...

Register

Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Thursday, 11 August 2022, 9:17 pm

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation